Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BIA 2-093 in Renal Impairment
NCT02281422Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eslicarbazepine acetate in epilepsy (5 arms), sponsored by BIAL. Primary endpoints: Peak Plasma Concentration at 96 hours and Area Under the Curve From Time Zero to 12h. Started Mar 2005; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02281422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281422.